{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Date of diagnosis for the locally advanced or metastatic or recurrent disease', 'TNM classification and disease stage at screening', 'Sampling method and the type of the tumor tissues for Nectin-4 mutation analysis', 'Previous treatment (including medication, radiotherapy and surgery) for underlying disease', '5.2.4 Performance Status', 'The ECOG PS Scale [Oken et al, 1982] will be used to assess performance status. Refer to', '[Appendix', '12.8', '5.3', 'Efficacy Assessments', 'Response and progression will be evaluated using RECIST v1.1 [Appendix', '12.71', 'Imaging for both Arms will be performed at screening/baseline and every 56 days ( 7 days)', 'from the first dose of study treatment throughout the study. Baseline imaging performed prior', 'to informed consent as standard of care may be used so long as it is performed within 28 days', 'prior to randomization. All subjects will have a bone scan (scintigraphy) performed at', 'screening/baseline. Subjects with positive bone scans at baseline will have a bone scan', 'performed every 56 days ( 7 days) throughout the study or more frequently if clinically', 'indicated. Subjects with negative bone scans at baseline should have a bone scan performed', 'if clinically indicated throughout the study even if not positive at baseline. Brain scans', '(CT with contrast/MRI) will only be performed if clinically indicated at screening/baseline and', 'repeated as clinically indicated or per standard of care throughout the study. If a subject', 'discontinues study drug prior to radiological disease progression, the subject should continue', 'to undergo imaging assessments every 56 days (7 days) until disease progression is', 'documented, or the subject starts another anticancer treatment whichever occurs earlier.', 'A CT scan with contrast (chest and abdomen) is the preferred modality for tumor assessment.', 'Magnetic resonance imaging is acceptable if local standard practice or if CT scans are', 'contraindicated in a subject (e.g., subject is allergic to contrast media). All other RECIST-', 'approved scanning methods such as x-ray are optional. Additional instructions for imaging', 'assessments can be found in the study procedures manual.', 'The assessment will include tumor measurements for target lesions, nontarget lesions and any', 'new lesions. An overall assessment will be characterized for a given time point evaluation. At', 'the end of study for that subject, the best overall response to the study regimen will be', 'characterized. To ensure comparability, the screening and subsequent assessment of response', 'should be performed using identical techniques. The same individual should assess images', 'for any 1 subject for the duration of the study if possible. For subjects with known brain', 'metastases at study entry, it is recommended that repeat imaging also include the brain and', 'the same methods used to detect brain lesions at Baseline are to be used to follow the lesions', 'throughout the study.', 'The site of disease progression including target, non-target and/or new lesions should be', 'documented in the eCRF. Additional imaging may be performed at any time to confirm', 'suspected progression of disease.', '14 Sep 2020', 'Astellas', 'Page 67 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'This study will be analyzed based on the results of local (investigator site) radiologic', 'assessments, including dates of progression and death. Since imaging scans may be needed', 'for future regulatory purposes or an independent review of all or a representative sample of', 'scans may be considered following the completion of PFS1 analysis, copies of all scans will', 'be collected throughout the study and stored centrally by a coordinating vendor. Images from', 'all randomized subjects will be sent to the imaging vendor according to the frequency of', 'Table 1', '5.3.1', 'Evaluation of Target Lesions', '5.3.1.1', 'Complete Response', 'CR is defined as disappearance of all target and nontarget lesions. Any pathological lymph', 'nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from', 'baseline measurement.', '5.3.1.2 Partial Response', 'PR is defined as at least a 30% decrease in the sum of diameters (longest for nonnodal', 'lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum', 'of diameters.', '5.3.1.3 Stable Disease', 'SD is defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify', 'for progressive disease taking as reference the smallest sum of diameters while on study', 'drug.', '5.3.1.4 Progressive Disease', 'PD is defined as at least a 20% increase in the sum of diameters (longest for nonnodal', 'lesions, short axis for nodal lesions) of the target lesions taking as reference the smallest sum', 'on study (this includes the baseline sum if that is the smallest on study). In addition to the', 'relative increase of 20%, the sum must also demonstrate an absolute increase of at least', '5 mm. The appearance of 1 or more new lesions is also considered progression.', '5.3.2', 'Evaluation of Nontarget Lesions', 'To achieve unequivocal progression on the basis of nontarget lesions, there must be an', 'overall level of substantial worsening in nontarget disease such that, even in presence of SD', 'or PR of target lesions, the overall tumor burden has increased sufficiently to merit', 'discontinuation of therapy. A modest increase in the size of 1 or more nontarget lesions is', 'usually not sufficient to qualify for unequivocal progression.', '5.3.2.1 Complete Response', 'For CR of nontarget lesions, subjects must have disappearance of all nontarget lesions and all', 'lymph nodes must be nonpathological in size (< 10 mm short axis).', '5.3.2.2 NonCR/NonPD', 'NonCR/NonPD of nontarget lesions is defined as persistence of 1 or more nontarget lesions.', '14 Sep 2020', 'Astellas', 'Page 68 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}